当前位置:首页>产品中心>单抗/多抗>Anti-Human CD93/C1qR Reference Antibody|抗人CD93/C1qR参照抗体(靶标:人CD93分子/C1q受体(研究用))

Anti-Human CD93/C1qR Reference Antibody|抗人CD93/C1qR参照抗体(靶标:人CD93分子/C1q受体(研究用))

  • 货号:RB9THV345026
  • 价格:面议
  • 点击:541
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Human
克隆性Monoclonal
抗体亚型IgG1, kappa
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
内毒素水平< 10 EU/mg
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
储存缓冲液0.01 M PBS pH 7.4
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -124°C long term.
产品使用说明ELISA: 1:2000-1:20000
登录号Q9NPY3
背景信息

Complement component C1q receptor (CD93/C1qR) is a ~68 kDa protein. Cell surface receptor that plays a role in various physiological processes including inflammation, phagocytosis, and cell adhesion. Plays a role in phagocytosis and enhances the uptake of apoptotic cells and immune complexes by acting as a receptor for defense collagens including surfactant protein A/SFTPA1, C1q, and mannose-binding lectin (MBL2). Plays a role in the regulation of endothelial cell function and adhesion by activating angiogenesis. Mechanistically, exerts its angiogenic function by associating with beta-dystroglycan, leading to SRC-dependent phosphorylation and subsequent recruitment of CBL. In turn, CBL provides a docking site for downstream signaling components, such as CRKL to enhance cell migration.

1. Geertsma, MF. et al. (1994) The American journal of physiology 267, L578-84. PMID: 7977768
2. Orlandini, M. et al. (2014) Oncotarget 5, 2750-60. PMID: 24809468
3. Galvagni, F. et al. (2016) Oncotarget 7, 10090-103. PMID: 26848865
4. Khan, KA. et al. (2017) Oncogene 36, 6097-6108. PMID: 28671670
5. Barbera, S. et al. (2023) International journal of biological macromolecules 224, 453-464. PMID: 36265539
6. Xu, Y. et al. (2024) Structure (London, England : 1993) 32, 282-291.e4. PMID: 38218180
备注For research use only.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 838
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 1125
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 771
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 969
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 767
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 900
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 635
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 702
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 777
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 913
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 1004
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 852
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 734
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 1023
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 1011
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 872
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 780
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 1029
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 872
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 693
总计 33037 个记录,共 1652 页,当前第 1650 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周日 9:00-22:30